Clinical Trials Directory

Trials / Not Yet Recruiting

Not Yet RecruitingNCT06738225

Serum MicroRNAs as Diagnostic Biomarkers of Colorectal Cancer

Status
Not Yet Recruiting
Phase
Study type
Observational
Enrollment
80 (estimated)
Sponsor
Bishoy Shehata · Academic / Other
Sex
All
Age
18 Years – 75 Years
Healthy volunteers
Accepted

Summary

evaluation the diagnostic value of certain MicroRNAs as biomarkers of Colorectal cancer by comparing its expression levels in Colorectal cancer patients and normal individuals.

Detailed description

Colorectal cancer (CRC) is the second commonest cause of cancer deaths and the third most common cancer worldwide. Five year survival of patients with stage 1 CRC is 92%, and decreases to 10% at stage 4 CRC. So, CRC diagnosing at an early stage is the most important factor influencing disease prognosis. Most CRC patients are diagnosed after being symptomatic, but studies show that once the symptoms are present it mostly signifies late-stage disease. colonoscopic screening of asymptomatic patients has been shown to pick up early-stage CRC. However, this is limited by cost issues and patient attitudes. Therefore, more efforts could be done to view to early diagnosis of CRC in asymptomatic patient. Biomarkers are molecules that can serve as signals of disease activity and pathological processes. CRC biomarkers can help in early diagnosis. MicroRNAs (miRNAs) are non-coding molecules that impact the expression of target genes in cell. Also, they exist in highly stable, cell free form in peripheral blood. They are detected by quantitative real time polymerase chain reaction (qRT-PCR). Data also shows that certain miRNAs are elevated in the plasma and tissues of CRC patients and decrease in plasma levels after operative treatment. There are over 2000 different miRNAs and they are estimated to regulate 30% of the human genome. miRNA dysregulation is also associated with multiple cancers. miRNAs seem to show significant promise with high sensitivity and specificity for CRC, but with limiting factors of limited data for high risk polyps and significant heterogeneity in test media and non-standardisation of test panels. Further research would be required to bridge these knowledge gaps. Interestingly, miR-15b and miR-21 appears to be the best diagnostic accuracy values for CRC.

Conditions

Interventions

TypeNameDescription
DIAGNOSTIC_TESTcertain serum MicroRNA biomarkers (miR-15b and miR-21)miR-15b and miR-21 as diagnostic biomarkers of colorectal cancer

Timeline

Start date
2025-03-01
Primary completion
2027-03-01
Completion
2027-05-01
First posted
2024-12-17
Last updated
2024-12-27

Source: ClinicalTrials.gov record NCT06738225. Inclusion in this directory is not an endorsement.